Filing Flows › Caris Life Sciences (CAI) › Q3 2025
Caris Life Sciences (CAI) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 5, 2025
Caris Life Sciences (CAI) reported revenue of $217M for the third quarter 2025 (Q3 2025), +113% from a year earlier and +20% from the quarter before. Operating margin was 15.1%, net earnings $24.3M (11.2% of revenue).
Caris Life Sciences, Q3 2025: revenue $217M (+113% year over year), operating margin 15.1%, net earnings $24.3M, operating cash flow $62.4M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $217M | +20% | +113% |
| Operating profit | $32.6M | — | — |
| Net earnings | $24.3M | — | — |
| Operating cash flow | $62.4M | +757% | — |
| Free cash flow | $55.3M | — | — |
What changed
Revenue was $216.8M in Q3 2025, up 113% year over year and up 20% from the previous quarter. Molecular Profiling Services was the largest line at 96% of revenue. Molecular Profiling Services added $113.8M year over year (up 121%), 99% of the total change.
Operating profit was $32.6M, a 15.1% margin (up 74.9 points year over year). Total costs grew 13% against revenue growth of 113%. The fastest-growing cost line was General & admin (+27%). Net earnings were $24.3M. The effective tax rate was 0.0%.
Operating cash flow was $62.4M, 257% of net earnings. Non-cash charges added back $4.9M of depreciation and amortization and $13.7M of share-based compensation. Working capital and other items added $19.5M. After purchases of property and equipment ($7.1M), free cash flow as the company reports it was $55.3M.
Questions
What was Caris Life Sciences' revenue in the third quarter 2025?
Caris Life Sciences (CAI) reported revenue of $217M for the third quarter 2025 (Q3 2025), +113% from a year earlier and +20% from the quarter before.
Was Caris Life Sciences profitable in the third quarter 2025?
Operating profit was $32.6M (15.1% of revenue) and net earnings $24.3M.